Research programme: targeted apoptosis stimulants - Antisoma

Drug Profile

Research programme: targeted apoptosis stimulants - Antisoma

Alternative Names: AS 1406; HMFG1-RNase; huHMFG1-RNase; TheraNase

Latest Information Update: 17 Sep 2007

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Antisoma; National Cancer Institute (USA)
  • Developer Antisoma
  • Class Immunoconjugates; Monoclonal antibodies
  • Mechanism of Action Apoptosis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 17 Sep 2007 Discontinued - Preclinical for Cancer in United Kingdom (Parenteral)
  • 30 Mar 2007 Preclinical development is ongoing
  • 13 Apr 2004 Data presented at the 95th Annual Meeting of the American Association for Cancer Research (AACR-2004) have been added to the Cancer pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top